Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia. The NODE-301 Trial
Phase of Trial: Phase III
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Etripamil (Primary)
- Indications Paroxysmal supraventricular tachycardia
- Focus Registrational; Therapeutic Use
- Acronyms NODE-301
- Sponsors Milestone Pharmaceuticals
- 04 Jul 2018 Status changed from not yet recruiting to recruiting.
- 07 Mar 2018 Status changed from planning to not yet recruiting.
- 26 Oct 2017 New trial record